Navigation Links
Progress made in HIV vaccine development

Researchers have successfully tested two candidate vaccines that may eventually be used together to confer immunity against HIV infection. Their findings are published in the December 15 issue of The Journal of Infectious Diseases, now available online.

Barney S. Graham, MD, PhD, and colleagues from the National Institutes of Health IH Vaccine Research Center in Maryland, the Fred Hutchinson Cancer Research Center in Seattle, and GenVec Incorporated tested two possible HIV vaccines with the hope of producing an immune response in healthy, uninfected adults. One was a plasmid DNA-based vaccine expressing genes from three dominant HIV subtypes, and the second used recombinant adenovirus serotype 5 (rAd5) as a vector to deliver similar HIV strains.

"Both approaches operate by gene delivery of customized vaccine antigens that are produced by host cells to initiate an immune response. DNA is simple and does not have the problem of anti-vector immunity. However, DNA may be less potent than vector-based gene delivery strategies. Replication-defective rAd5 has the advantage of targeted, efficient gene delivery and high potency, but may be susceptible to anti-vector immunity," said Graham.

Both vaccines were tested in healthy uninfected adult volunteers. The DNA vaccine was found safe and well-tolerated. By week 12 following immunization, 97.5% of vaccinees experienced positive CD4 T cell responses and 40% experienced positive CD8 T cell responses.

The recombinant vector vaccine was also well-tolerated, but higher doses led to some adverse events such as pain and fever. By week 4 following immunization, 93.3% of vaccinees experienced positive CD4 T cell responses, and 60% experienced positive CD8 T cell responses.

"HIV-specific CD8 cell responses clear virus infected cells, and appear during the declining viremia following acute infection," explained Graham. "HIV-specific CD4 responses also peak early in infection; however
'"/>

Source:Infectious Diseases Society of America


Page: 1 2

Related biology news :

1. Bevacizumab Combined With Chemotherapy Improves Progression-Free Survival for Patients With Advanced Breast Cancer
2. AIDS Public Awareness Campaign Expands Following Report Of Rapidly Progressive HIV
3. Progress on HIV/AIDS significant but insufficient
4. Progress being made in exploring potential use of stem cells to treat heart disease
5. Progress toward artificial photosynthesis?
6. Research advances quest for HIV-1 vaccine
7. A much-needed shot in the arm for HIV vaccine development
8. Discovery of key proteins shape could lead to improved bacterial pneumonia vaccine
9. Gene vaccine for Alzheimers disease shows promising results
10. Influenza vaccine uses insect cells to speed development
11. Norovirus, AIDS vaccine and Hepatitis Virus
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Progress made HIV vaccine development

(Date:5/11/2015)... , May 11, 2015  Synaptics Incorporated ... human interface solutions, today announced the appointment of ... and Chief Financial Officer, reporting to Rick ... Synaptics, current Chief Financial Officer, Kathleen Bayless ... Mr. Ali brings extensive financial ...
(Date:5/7/2015)... May 7, 2015 Fingerprint ... FPC1022 and FPC1035, FPC,s smallest touch fingerprint sensors ... mainly considered for integration on the backside of ... OEMs increased possibilities to integrate touch fingerprint sensors ... also improves possibilities for module manufacturers to customize ...
(Date:4/27/2015)... Fla. , Apr. 27, 2015 Profile ... access control and security systems is pleased to announce ... company as a consultant and member of its scientific ... is widely known as a thought leader in technology-enhanced ... Learning Technology Group, and has published studies and books ...
Breaking Biology News(10 mins):Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4
... aimed at protecting human health by improving how chemicals ... test 10,000 compounds for potential toxicity. The compounds cover ... food additives, chemicals found in industrial processes, and human ... is publicly available at http://www.epa.gov/ncct/dsstox . Testing ...
... monitoring firefighters working at prescribed burns in the southeastern ... decreased with successive days of exposure to smoke and ... decline in lung function across work seasons," said Olorunfemi ... the study published recently in the journal Inhalation ...
... game players have helped significantly advance our understanding of ... and cancer over the past year. They are the ... Jrme Waldispuhl of the McGill School of Computer Science ... casual game players to contribute to scientific research by ...
Cached Biology News:US Tox21 to begin screening 10,000 chemicals 2US Tox21 to begin screening 10,000 chemicals 3UGA study documents lung function declines in firefighters working at prescribed burns 2Video game players advancing genetic research 2
(Date:5/28/2015)... 2015 Celsion Corporation (the "Company") (NASDAQ: ... from two institutional healthcare investors to purchase an aggregate ... in an at-the-market registered direct offering and a concurrent ... The Company entered into a definitive purchase agreement ... to sell an aggregate of 3,000,000 shares of its ...
(Date:5/28/2015)... McKinney, Texas (PRWEB) May 28, 2015 ... products for use in applications such as animal ... fat and oil reduction in wastewater treatment plants ... be attending the World Pork Expo, June 3-5 ... earlier this year in a Wall Street Journal ...
(Date:5/28/2015)... NORTH BRUNSWICK, N.J. , May 28, 2015 ... that PDS0101, a cancer immunotherapy treatment targeting HPV-16, ... patients.  Currently, pre-cervical cancer is ... could offer a simple and effective non-surgical alternative. ... body,s defense mechanisms (T-cells) to recognize, target, and ...
(Date:5/28/2015)... BEACH, Fla. , May 28, 2015 ... supporting the anti-cancer potential of its growth hormone-releasing hormone ... at the 2015 ASCO Annual Meeting. The data ... target for Biscayne,s anti-cancer GHRH blockers, is present on ... status. These findings suggest that GHRH antagonists could have ...
Breaking Biology Technology:Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 3DryLet to Showcase Patented ManureMagicâ„¢ at the 2015 World Pork Expo, June 3-5 in Des Moines, Iowa 2PDS Biotechnology reports positive Phase I clinical trial results in proprietary HPV-Cancer Immunotherapy 2Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 2Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 3
... Inclinix, Inc. has announced today that it has ... (Nasdaq: DATA ) to offer the most ... device companies globally. , ... DATATRAK,s eClinical(TM) platform to enhance its services as a ...
... Md., April 30 /PRNewswire/ -- ... company developing novel, proprietary antibodies for the treatment of ... will host a conference call and audio webcast on ... (3:00 pm Central European Time) to discuss its financial ...
... Inc. (NASDAQ: AEZS , TSX: AEZ), a ... will announce its first quarter 2009 financial and operating ... The Company will host a conference call and webcast ... 3:30 p.m., Eastern Time. , Participants may access the ...
Cached Biology Technology:DATATRAK International, Inc. Forms Strategic Partnership with Inclinix, Inc. 2DATATRAK International, Inc. Forms Strategic Partnership with Inclinix, Inc. 3DATATRAK International, Inc. Forms Strategic Partnership with Inclinix, Inc. 4Micromet, Inc. to Host Conference Call and Webcast to Report First Quarter 2009 Financial Results on May 6, 2009 2Micromet, Inc. to Host Conference Call and Webcast to Report First Quarter 2009 Financial Results on May 6, 2009 3Micromet, Inc. to Host Conference Call and Webcast to Report First Quarter 2009 Financial Results on May 6, 2009 4
... anti-Human Alpha 1 Acid Glycoprotein ... Goats were immunized with ... in Freund's adjuvant. The ... to ensure specificity. For ...
...
... Development kit contains the basic components required ... measure natural and recombinant canine Monocyte Chemotactic ... and serum.1 Each kit contains sufficient materials ... plates, provided that the following conditions are ...
Mouse monoclonal [LPL4A.1] to Plastin L ( Abpromise for all tested applications). SwissProtID: P13796...
Biology Products: